News FDA declines to approve needle-free epinephrine from ARS Shares in ARS Pharmaceuticals were in freefall in pre-market trading this morning as it emerged that the FDA had declined to approve its application for its lead product,
Views & Analysis What doctors say about EpiPen pricing The furore over Mylan’s ‘price gouging’ in relation to EpiPen in the US went global, thanks to social media.
News Mylan responds to price backlash with generic EpiPen Company launches cut-price generic alongside existing branded version
News Third death reported with a Sarepta gene therapy A third fatality has been recorded among patients receiving treatment with a Sarepta gene therapy, adding to the troubles being faced by the company.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face